The present invention pertains to a therapeutic agent for ophthalmic diseases which comprises a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in the form of nanoparticles tending to be retained in a posterior ocular tissue when systemically administered.本發明係關於一種眼科疾病治療劑,其包含奈米粒子形態之具有於全身投予之情形時滯留於眼後段組織之性質的血管內皮生長因子(VEGF)受體抑制劑或上皮生長因子(EGF)受體抑制劑。